Welcome to LookChem.com Sign In|Join Free

CAS

  • or
bullatacin is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

102989-24-2 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 2(5H)-Furanone,3-[(2R,13R)-2,13-dihydroxy-13-[(2R,2'R,5R,5'R)-octahydro-5'-[(1R)-1-hydroxyundecyl][2,2'-bifuran]-5-yl]tridecyl]-5-methyl-,(5S)-

    Cas No: 102989-24-2

  • USD $ 100.0-100.0 / Gram

  • 1 Gram

  • 10 Metric Ton/Day

  • HENAN NEW BLUE CHEMICAL CO.,LTD
  • Contact Supplier
  • 102989-24-2 Structure
  • Basic information

    1. Product Name: bullatacin
    2. Synonyms: bullatacin
    3. CAS NO:102989-24-2
    4. Molecular Formula: C37H66O7
    5. Molecular Weight: 622.921
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 102989-24-2.mol
  • Chemical Properties

    1. Melting Point: 45-48 °C(Solv: methanol (67-56-1); water (7732-18-5))
    2. Boiling Point: 745.5°Cat760mmHg
    3. Flash Point: 220.3°C
    4. Appearance: /
    5. Density: 1.054g/cm3
    6. Vapor Pressure: 1.19E-25mmHg at 25°C
    7. Refractive Index: 1.508
    8. Storage Temp.: N/A
    9. Solubility: N/A
    10. PKA: 14.46±0.20(Predicted)
    11. CAS DataBase Reference: bullatacin(CAS DataBase Reference)
    12. NIST Chemistry Reference: bullatacin(102989-24-2)
    13. EPA Substance Registry System: bullatacin(102989-24-2)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 102989-24-2(Hazardous Substances Data)

102989-24-2 Usage

Anticancer Research

Bullatacin is a bis(tetrahydrofuranoid) fatty acid lactone found in some fruits fromAnnonaceae family. It is a member of acetogenin class of phytochemicals. It fightsagainst the MDR phenotype of human mammary adenocarcinoma. It has showsantitumor properties by induction of chromatin migration and tumor cellcondensation followed by apoptosis (Oberlies et al. 1997; Desai et al. 2008).

Check Digit Verification of cas no

The CAS Registry Mumber 102989-24-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,2,9,8 and 9 respectively; the second part has 2 digits, 2 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 102989-24:
(8*1)+(7*0)+(6*2)+(5*9)+(4*8)+(3*9)+(2*2)+(1*4)=132
132 % 10 = 2
So 102989-24-2 is a valid CAS Registry Number.
InChI:InChI=1/C37H66O7/c1-3-4-5-6-7-11-14-17-20-31(39)33-22-24-35(43-33)36-25-23-34(44-36)32(40)21-18-15-12-9-8-10-13-16-19-30(38)27-29-26-28(2)42-37(29)41/h26,28,30-36,38-40H,3-25,27H2,1-2H3/t28-,30-,31+,32+,33+,34+,35+,36+/m0/s1

102989-24-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name (+)-asimicin

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:102989-24-2 SDS

102989-24-2Synthetic route

C59H86O8

C59H86O8

(+)-asimicin
102989-24-2

(+)-asimicin

Conditions
ConditionsYield
With 2,3-dicyano-5,6-dichloro-p-benzoquinone In aq. phosphate buffer; water; 1,2-dichloro-ethane at 50℃; for 2h;98%
C49H94O7Si2
1086569-84-7

C49H94O7Si2

(+)-asimicin
102989-24-2

(+)-asimicin

Conditions
ConditionsYield
With hydrogen fluoride In tetrahydrofuran; acetonitrile at 20℃; for 12h; Inert atmosphere;91%
(S)-3-{(2S,13S)-2-(tert-Butyl-dimethyl-silanyloxy)-13-methoxymethoxy-13-[(2R,5R,2'R,5'R)-5'-((S)-1-methoxymethoxy-undecyl)-octahydro-[2,2']bifuranyl-5-yl]-tridecyl}-5-methyl-5H-furan-2-one

(S)-3-{(2S,13S)-2-(tert-Butyl-dimethyl-silanyloxy)-13-methoxymethoxy-13-[(2R,5R,2'R,5'R)-5'-((S)-1-methoxymethoxy-undecyl)-octahydro-[2,2']bifuranyl-5-yl]-tridecyl}-5-methyl-5H-furan-2-one

(+)-asimicin
102989-24-2

(+)-asimicin

Conditions
ConditionsYield
With acetyl chloride In methanol; dichloromethane at 20℃; for 2h; Elimination;83%
(S)-3-((2R,13R)-2,13-Bis-(2-trimethylsilanyl-ethoxymethoxy)-13-{(2R,5R,2'R,5'R)-5'-[(R)-1-(2-trimethylsilanyl-ethoxymethoxy)-undecyl]-octahydro-[2,2']bifuranyl-5-yl}-tridecyl)-5-methyl-5H-furan-2-one
193812-20-3

(S)-3-((2R,13R)-2,13-Bis-(2-trimethylsilanyl-ethoxymethoxy)-13-{(2R,5R,2'R,5'R)-5'-[(R)-1-(2-trimethylsilanyl-ethoxymethoxy)-undecyl]-octahydro-[2,2']bifuranyl-5-yl}-tridecyl)-5-methyl-5H-furan-2-one

(+)-asimicin
102989-24-2

(+)-asimicin

Conditions
ConditionsYield
With pyridinium p-toluenesulfonate In ethanol at 40℃; for 16h;67%
(S)-3-{(2R,13R)-2-Hydroxy-13-methoxymethoxy-13-[(2R,5R,2'R,5'R)-5'-((R)-1-methoxymethoxy-undecyl)-octahydro-[2,2']bifuranyl-5-yl]-tridecyl}-5-methyl-5H-furan-2-one
507480-65-1

(S)-3-{(2R,13R)-2-Hydroxy-13-methoxymethoxy-13-[(2R,5R,2'R,5'R)-5'-((R)-1-methoxymethoxy-undecyl)-octahydro-[2,2']bifuranyl-5-yl]-tridecyl}-5-methyl-5H-furan-2-one

(+)-asimicin
102989-24-2

(+)-asimicin

Conditions
ConditionsYield
With hydrogenchloride In tetrahydrofuran; methanol at 20℃; for 15h;57%
(S)-3-{(E)-(2R,13R)-2-(tert-Butyl-diphenyl-silanyloxy)-13-hydroxy-13-[(2R,5R,2'R,5'R)-5'-((R)-1-hydroxy-undecyl)-octahydro-[2,2']bifuranyl-5-yl]-tridec-8-en-10-ynyl}-5-methyl-5H-furan-2-one

(S)-3-{(E)-(2R,13R)-2-(tert-Butyl-diphenyl-silanyloxy)-13-hydroxy-13-[(2R,5R,2'R,5'R)-5'-((R)-1-hydroxy-undecyl)-octahydro-[2,2']bifuranyl-5-yl]-tridec-8-en-10-ynyl}-5-methyl-5H-furan-2-one

(+)-asimicin
102989-24-2

(+)-asimicin

Conditions
ConditionsYield
With Wilkinson's catalyst; hydrogen; acetyl chloride 1.) benzene,2.) MeOH, Et2O; Yield given. Multistep reaction;
(S)-3-{(2R,13R)-2,13-Bis-methoxymethoxy-13-[(2R,5R,2'R,5'R)-5'-((R)-1-methoxymethoxy-undecyl)-octahydro-[2,2']bifuranyl-5-yl]-tridecyl}-5-methyl-5H-furan-2-one

(S)-3-{(2R,13R)-2,13-Bis-methoxymethoxy-13-[(2R,5R,2'R,5'R)-5'-((R)-1-methoxymethoxy-undecyl)-octahydro-[2,2']bifuranyl-5-yl]-tridecyl}-5-methyl-5H-furan-2-one

(+)-asimicin
102989-24-2

(+)-asimicin

Conditions
ConditionsYield
With dimethylsulfide; boron trifluoride diethyl etherate In dichloromethane for 0.5h; 0 deg C -> r.t.;
Trifluoro-acetic acid (1R,12R)-13-((S)-5-methyl-2-oxo-2,5-dihydro-furan-3-yl)-12-(2,2,2-trifluoro-acetoxy)-1-{(2R,5R,2'R,5'R)-5'-[(R)-1-(2,2,2-trifluoro-acetoxy)-undecyl]-octahydro-[2,2']bifuranyl-5-yl}-tridecyl ester

Trifluoro-acetic acid (1R,12R)-13-((S)-5-methyl-2-oxo-2,5-dihydro-furan-3-yl)-12-(2,2,2-trifluoro-acetoxy)-1-{(2R,5R,2'R,5'R)-5'-[(R)-1-(2,2,2-trifluoro-acetoxy)-undecyl]-octahydro-[2,2']bifuranyl-5-yl}-tridecyl ester

(+)-asimicin
102989-24-2

(+)-asimicin

Conditions
ConditionsYield
With potassium cyanide In methanol for 0.333333h;
(2R,4R,5S)-5-[(1R)-1-(tert-butyldimethylsilanyloxy)undecyl]-4-(dimethylphanylsilanyl)tetrahydrofuran-2-carbaldehyde
863604-39-1

(2R,4R,5S)-5-[(1R)-1-(tert-butyldimethylsilanyloxy)undecyl]-4-(dimethylphanylsilanyl)tetrahydrofuran-2-carbaldehyde

(+)-asimicin
102989-24-2

(+)-asimicin

Conditions
ConditionsYield
Multi-step reaction with 6 steps
1: 4 Angstroem molecular sieves; SnCl4 / CH2Cl2 / -40 °C
2: TBAF / dimethylformamide; tetrahydrofuran / 6 h / 90 °C
3: 0.5 h / 20 °C
4: Pd(PPh3)4; water / tetrahydrofuran / 2 h / 20 °C
5: AgNO3/SiO2 / hexane; CH2Cl2 / 2 h
6: KCN / methanol / 0.33 h
View Scheme
Multi-step reaction with 6 steps
1: 4 Angstroem molecular sieves; SnCl4 / CH2Cl2 / 4 h / 0 °C
2: TBAF / dimethylformamide; tetrahydrofuran / 6 h / 90 °C
3: 0.5 h / 20 °C
4: Pd(PPh3)4; water / tetrahydrofuran / 2 h / 20 °C
5: AgNO3/SiO2 / hexane; CH2Cl2 / 2 h
6: KCN / methanol / 0.33 h
View Scheme
(2R,4R,5S)-[5-[(1R)-1-(tert-butyldimethylsilanyloxy)undecyl]-4-(dimethylphenylsilanyl)tetrahydrofuran-2-yl]methanol
863604-46-0

(2R,4R,5S)-[5-[(1R)-1-(tert-butyldimethylsilanyloxy)undecyl]-4-(dimethylphenylsilanyl)tetrahydrofuran-2-yl]methanol

(+)-asimicin
102989-24-2

(+)-asimicin

Conditions
ConditionsYield
Multi-step reaction with 7 steps
1: diisopropylethyl amine; DMSO; SO3*pyridine / CH2Cl2 / 1 h / 0 °C
2: 4 Angstroem molecular sieves; SnCl4 / CH2Cl2 / -40 °C
3: TBAF / dimethylformamide; tetrahydrofuran / 6 h / 90 °C
4: 0.5 h / 20 °C
5: Pd(PPh3)4; water / tetrahydrofuran / 2 h / 20 °C
6: AgNO3/SiO2 / hexane; CH2Cl2 / 2 h
7: KCN / methanol / 0.33 h
View Scheme
Multi-step reaction with 7 steps
1: diisopropylethyl amine; DMSO; SO3*pyridine / CH2Cl2 / 1 h / 0 °C
2: 4 Angstroem molecular sieves; SnCl4 / CH2Cl2 / 4 h / 0 °C
3: TBAF / dimethylformamide; tetrahydrofuran / 6 h / 90 °C
4: 0.5 h / 20 °C
5: Pd(PPh3)4; water / tetrahydrofuran / 2 h / 20 °C
6: AgNO3/SiO2 / hexane; CH2Cl2 / 2 h
7: KCN / methanol / 0.33 h
View Scheme
(2S,3R,5R)-5-(benzyloxymethyl)-2-[(1R)-1-(tert-butyldimethylsilanyloxy)undecyl]-3-(dimethylphenylsilanyl)tetrahydrofuran
863604-38-0

(2S,3R,5R)-5-(benzyloxymethyl)-2-[(1R)-1-(tert-butyldimethylsilanyloxy)undecyl]-3-(dimethylphenylsilanyl)tetrahydrofuran

(+)-asimicin
102989-24-2

(+)-asimicin

Conditions
ConditionsYield
Multi-step reaction with 8 steps
1: Pd(OH)2; H2 / tetrahydrofuran / 2 h / 20 °C
2: diisopropylethyl amine; DMSO; SO3*pyridine / CH2Cl2 / 1 h / 0 °C
3: 4 Angstroem molecular sieves; SnCl4 / CH2Cl2 / -40 °C
4: TBAF / dimethylformamide; tetrahydrofuran / 6 h / 90 °C
5: 0.5 h / 20 °C
6: Pd(PPh3)4; water / tetrahydrofuran / 2 h / 20 °C
7: AgNO3/SiO2 / hexane; CH2Cl2 / 2 h
8: KCN / methanol / 0.33 h
View Scheme
Multi-step reaction with 8 steps
1: Pd(OH)2; H2 / tetrahydrofuran / 2 h / 20 °C
2: diisopropylethyl amine; DMSO; SO3*pyridine / CH2Cl2 / 1 h / 0 °C
3: 4 Angstroem molecular sieves; SnCl4 / CH2Cl2 / 4 h / 0 °C
4: TBAF / dimethylformamide; tetrahydrofuran / 6 h / 90 °C
5: 0.5 h / 20 °C
6: Pd(PPh3)4; water / tetrahydrofuran / 2 h / 20 °C
7: AgNO3/SiO2 / hexane; CH2Cl2 / 2 h
8: KCN / methanol / 0.33 h
View Scheme
(2R,2'R,5R,5'R)-5-[(1R)-1-hydroxyundecyl]-5'-[(1R,12R,16R)-1,12,16-trihydroxyheptadec-14-yne]octahydro-2,2'-bifuran
857635-07-5

(2R,2'R,5R,5'R)-5-[(1R)-1-hydroxyundecyl]-5'-[(1R,12R,16R)-1,12,16-trihydroxyheptadec-14-yne]octahydro-2,2'-bifuran

(+)-asimicin
102989-24-2

(+)-asimicin

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: 0.5 h / 20 °C
2: Pd(PPh3)4; water / tetrahydrofuran / 2 h / 20 °C
3: AgNO3/SiO2 / hexane; CH2Cl2 / 2 h
4: KCN / methanol / 0.33 h
View Scheme
(3S,4R,15R,19R)-4,15-bis(tert-bytyldimethylsilanyloxy)-19-(tert-butyldiphenylsilanyloxy)-3-(dimethylphenylsilanyl)eicos-1-en-17-yne
863604-34-6

(3S,4R,15R,19R)-4,15-bis(tert-bytyldimethylsilanyloxy)-19-(tert-butyldiphenylsilanyloxy)-3-(dimethylphenylsilanyl)eicos-1-en-17-yne

(+)-asimicin
102989-24-2

(+)-asimicin

Conditions
ConditionsYield
Multi-step reaction with 6 steps
1: 4 Angstroem molecular sieves; SnCl4 / CH2Cl2 / -40 °C
2: TBAF / dimethylformamide; tetrahydrofuran / 6 h / 90 °C
3: 0.5 h / 20 °C
4: Pd(PPh3)4; water / tetrahydrofuran / 2 h / 20 °C
5: AgNO3/SiO2 / hexane; CH2Cl2 / 2 h
6: KCN / methanol / 0.33 h
View Scheme
Multi-step reaction with 6 steps
1: 4 Angstroem molecular sieves; SnCl4 / CH2Cl2 / 4 h / 0 °C
2: TBAF / dimethylformamide; tetrahydrofuran / 6 h / 90 °C
3: 0.5 h / 20 °C
4: Pd(PPh3)4; water / tetrahydrofuran / 2 h / 20 °C
5: AgNO3/SiO2 / hexane; CH2Cl2 / 2 h
6: KCN / methanol / 0.33 h
View Scheme
(12R,16R)-12-(tert-butyldimethylsilanyloxy)-16-(tert-butyldiphenylsilanyloxy)heptadec-14-ynal
863604-44-8

(12R,16R)-12-(tert-butyldimethylsilanyloxy)-16-(tert-butyldiphenylsilanyloxy)heptadec-14-ynal

(+)-asimicin
102989-24-2

(+)-asimicin

Conditions
ConditionsYield
Multi-step reaction with 8 steps
1.1: BF3*Et2O / tetrahydrofuran; hexane / 0.08 h / -78 °C
1.2: tetrahydrofuran; hexane / 4 h / -78 °C
1.3: 340 mg / aq. H2O2 / tetrahydrofuran; hexane; aq. phosphate buffer / 16 h / 20 °C
2.1: 85 percent / imidazole / various solvent(s) / 72 h / 40 °C
3.1: 4 Angstroem molecular sieves; SnCl4 / CH2Cl2 / -40 °C
4.1: TBAF / dimethylformamide; tetrahydrofuran / 6 h / 90 °C
5.1: 0.5 h / 20 °C
6.1: Pd(PPh3)4; water / tetrahydrofuran / 2 h / 20 °C
7.1: AgNO3/SiO2 / hexane; CH2Cl2 / 2 h
8.1: KCN / methanol / 0.33 h
View Scheme
Multi-step reaction with 8 steps
1.1: BF3*Et2O / tetrahydrofuran; hexane / 0.08 h / -78 °C
1.2: tetrahydrofuran; hexane / 4 h / -78 °C
1.3: 340 mg / aq. H2O2 / tetrahydrofuran; hexane; aq. phosphate buffer / 16 h / 20 °C
2.1: 85 percent / imidazole / various solvent(s) / 72 h / 40 °C
3.1: 4 Angstroem molecular sieves; SnCl4 / CH2Cl2 / 4 h / 0 °C
4.1: TBAF / dimethylformamide; tetrahydrofuran / 6 h / 90 °C
5.1: 0.5 h / 20 °C
6.1: Pd(PPh3)4; water / tetrahydrofuran / 2 h / 20 °C
7.1: AgNO3/SiO2 / hexane; CH2Cl2 / 2 h
8.1: KCN / methanol / 0.33 h
View Scheme
(12R,16R)-2,2-dimethylpropionic acid 16-(tert-butyldiphenylsilanyloxy)-12-hydroxyheptadec-14-ynyl ester
863604-43-7

(12R,16R)-2,2-dimethylpropionic acid 16-(tert-butyldiphenylsilanyloxy)-12-hydroxyheptadec-14-ynyl ester

(+)-asimicin
102989-24-2

(+)-asimicin

Conditions
ConditionsYield
Multi-step reaction with 11 steps
1.1: 93 percent / triethylamine; DMAP / CH2Cl2 / 24 h / 20 °C
2.1: 97 percent / diisobutylaluminum hydride / CH2Cl2; hexane / 0.5 h / -78 °C
3.1: 97 percent / DMSO; diisopropylethylamine; SO3*pyridine / CH2Cl2 / 1 h / 0 °C
4.1: BF3*Et2O / tetrahydrofuran; hexane / 0.08 h / -78 °C
4.2: tetrahydrofuran; hexane / 4 h / -78 °C
4.3: 340 mg / aq. H2O2 / tetrahydrofuran; hexane; aq. phosphate buffer / 16 h / 20 °C
5.1: 85 percent / imidazole / various solvent(s) / 72 h / 40 °C
6.1: 4 Angstroem molecular sieves; SnCl4 / CH2Cl2 / -40 °C
7.1: TBAF / dimethylformamide; tetrahydrofuran / 6 h / 90 °C
8.1: 0.5 h / 20 °C
9.1: Pd(PPh3)4; water / tetrahydrofuran / 2 h / 20 °C
10.1: AgNO3/SiO2 / hexane; CH2Cl2 / 2 h
11.1: KCN / methanol / 0.33 h
View Scheme
Multi-step reaction with 11 steps
1.1: 93 percent / triethylamine; DMAP / CH2Cl2 / 24 h / 20 °C
2.1: 97 percent / diisobutylaluminum hydride / CH2Cl2; hexane / 0.5 h / -78 °C
3.1: 97 percent / DMSO; diisopropylethylamine; SO3*pyridine / CH2Cl2 / 1 h / 0 °C
4.1: BF3*Et2O / tetrahydrofuran; hexane / 0.08 h / -78 °C
4.2: tetrahydrofuran; hexane / 4 h / -78 °C
4.3: 340 mg / aq. H2O2 / tetrahydrofuran; hexane; aq. phosphate buffer / 16 h / 20 °C
5.1: 85 percent / imidazole / various solvent(s) / 72 h / 40 °C
6.1: 4 Angstroem molecular sieves; SnCl4 / CH2Cl2 / 4 h / 0 °C
7.1: TBAF / dimethylformamide; tetrahydrofuran / 6 h / 90 °C
8.1: 0.5 h / 20 °C
9.1: Pd(PPh3)4; water / tetrahydrofuran / 2 h / 20 °C
10.1: AgNO3/SiO2 / hexane; CH2Cl2 / 2 h
11.1: KCN / methanol / 0.33 h
View Scheme
(12R,16R)-12-(tert-butyldimethylsilanyloxy)-16-(tert-butyldiphenylsilanyloxy)heptadec-14-yn-1-ol
863604-52-8

(12R,16R)-12-(tert-butyldimethylsilanyloxy)-16-(tert-butyldiphenylsilanyloxy)heptadec-14-yn-1-ol

(+)-asimicin
102989-24-2

(+)-asimicin

Conditions
ConditionsYield
Multi-step reaction with 9 steps
1.1: 97 percent / DMSO; diisopropylethylamine; SO3*pyridine / CH2Cl2 / 1 h / 0 °C
2.1: BF3*Et2O / tetrahydrofuran; hexane / 0.08 h / -78 °C
2.2: tetrahydrofuran; hexane / 4 h / -78 °C
2.3: 340 mg / aq. H2O2 / tetrahydrofuran; hexane; aq. phosphate buffer / 16 h / 20 °C
3.1: 85 percent / imidazole / various solvent(s) / 72 h / 40 °C
4.1: 4 Angstroem molecular sieves; SnCl4 / CH2Cl2 / -40 °C
5.1: TBAF / dimethylformamide; tetrahydrofuran / 6 h / 90 °C
6.1: 0.5 h / 20 °C
7.1: Pd(PPh3)4; water / tetrahydrofuran / 2 h / 20 °C
8.1: AgNO3/SiO2 / hexane; CH2Cl2 / 2 h
9.1: KCN / methanol / 0.33 h
View Scheme
Multi-step reaction with 9 steps
1.1: 97 percent / DMSO; diisopropylethylamine; SO3*pyridine / CH2Cl2 / 1 h / 0 °C
2.1: BF3*Et2O / tetrahydrofuran; hexane / 0.08 h / -78 °C
2.2: tetrahydrofuran; hexane / 4 h / -78 °C
2.3: 340 mg / aq. H2O2 / tetrahydrofuran; hexane; aq. phosphate buffer / 16 h / 20 °C
3.1: 85 percent / imidazole / various solvent(s) / 72 h / 40 °C
4.1: 4 Angstroem molecular sieves; SnCl4 / CH2Cl2 / 4 h / 0 °C
5.1: TBAF / dimethylformamide; tetrahydrofuran / 6 h / 90 °C
6.1: 0.5 h / 20 °C
7.1: Pd(PPh3)4; water / tetrahydrofuran / 2 h / 20 °C
8.1: AgNO3/SiO2 / hexane; CH2Cl2 / 2 h
9.1: KCN / methanol / 0.33 h
View Scheme
(12R,16R)-2,2-dimethylpropionic acid 16-(tert-butyldiphenylsilanyloxy)-12-(tert-budyldimethylsilanyloxy)heptadec-14-ynyl ester
863604-51-7

(12R,16R)-2,2-dimethylpropionic acid 16-(tert-butyldiphenylsilanyloxy)-12-(tert-budyldimethylsilanyloxy)heptadec-14-ynyl ester

(+)-asimicin
102989-24-2

(+)-asimicin

Conditions
ConditionsYield
Multi-step reaction with 10 steps
1.1: 97 percent / diisobutylaluminum hydride / CH2Cl2; hexane / 0.5 h / -78 °C
2.1: 97 percent / DMSO; diisopropylethylamine; SO3*pyridine / CH2Cl2 / 1 h / 0 °C
3.1: BF3*Et2O / tetrahydrofuran; hexane / 0.08 h / -78 °C
3.2: tetrahydrofuran; hexane / 4 h / -78 °C
3.3: 340 mg / aq. H2O2 / tetrahydrofuran; hexane; aq. phosphate buffer / 16 h / 20 °C
4.1: 85 percent / imidazole / various solvent(s) / 72 h / 40 °C
5.1: 4 Angstroem molecular sieves; SnCl4 / CH2Cl2 / -40 °C
6.1: TBAF / dimethylformamide; tetrahydrofuran / 6 h / 90 °C
7.1: 0.5 h / 20 °C
8.1: Pd(PPh3)4; water / tetrahydrofuran / 2 h / 20 °C
9.1: AgNO3/SiO2 / hexane; CH2Cl2 / 2 h
10.1: KCN / methanol / 0.33 h
View Scheme
Multi-step reaction with 10 steps
1.1: 97 percent / diisobutylaluminum hydride / CH2Cl2; hexane / 0.5 h / -78 °C
2.1: 97 percent / DMSO; diisopropylethylamine; SO3*pyridine / CH2Cl2 / 1 h / 0 °C
3.1: BF3*Et2O / tetrahydrofuran; hexane / 0.08 h / -78 °C
3.2: tetrahydrofuran; hexane / 4 h / -78 °C
3.3: 340 mg / aq. H2O2 / tetrahydrofuran; hexane; aq. phosphate buffer / 16 h / 20 °C
4.1: 85 percent / imidazole / various solvent(s) / 72 h / 40 °C
5.1: 4 Angstroem molecular sieves; SnCl4 / CH2Cl2 / 4 h / 0 °C
6.1: TBAF / dimethylformamide; tetrahydrofuran / 6 h / 90 °C
7.1: 0.5 h / 20 °C
8.1: Pd(PPh3)4; water / tetrahydrofuran / 2 h / 20 °C
9.1: AgNO3/SiO2 / hexane; CH2Cl2 / 2 h
10.1: KCN / methanol / 0.33 h
View Scheme
(3S,4R,15R,19R)-15-(tert-butyldimethylsilanyloxy)-19-(tert-butyldiphenylsilanyloxy)-3-(dimethylphenylsilanyl)eicos-1-en-17-yn-4-ol
863604-53-9

(3S,4R,15R,19R)-15-(tert-butyldimethylsilanyloxy)-19-(tert-butyldiphenylsilanyloxy)-3-(dimethylphenylsilanyl)eicos-1-en-17-yn-4-ol

(+)-asimicin
102989-24-2

(+)-asimicin

Conditions
ConditionsYield
Multi-step reaction with 7 steps
1: 85 percent / imidazole / various solvent(s) / 72 h / 40 °C
2: 4 Angstroem molecular sieves; SnCl4 / CH2Cl2 / -40 °C
3: TBAF / dimethylformamide; tetrahydrofuran / 6 h / 90 °C
4: 0.5 h / 20 °C
5: Pd(PPh3)4; water / tetrahydrofuran / 2 h / 20 °C
6: AgNO3/SiO2 / hexane; CH2Cl2 / 2 h
7: KCN / methanol / 0.33 h
View Scheme
Multi-step reaction with 7 steps
1: 85 percent / imidazole / various solvent(s) / 72 h / 40 °C
2: 4 Angstroem molecular sieves; SnCl4 / CH2Cl2 / 4 h / 0 °C
3: TBAF / dimethylformamide; tetrahydrofuran / 6 h / 90 °C
4: 0.5 h / 20 °C
5: Pd(PPh3)4; water / tetrahydrofuran / 2 h / 20 °C
6: AgNO3/SiO2 / hexane; CH2Cl2 / 2 h
7: KCN / methanol / 0.33 h
View Scheme
Trifluoro-acetic acid (1R,12R,16R)-12,16-bis-(2,2,2-trifluoro-acetoxy)-1-{(2R,5R,2'R,5'R)-5'-[(R)-1-(2,2,2-trifluoro-acetoxy)-undecyl]-octahydro-[2,2']bifuranyl-5-yl}-heptadec-14-ynyl ester

Trifluoro-acetic acid (1R,12R,16R)-12,16-bis-(2,2,2-trifluoro-acetoxy)-1-{(2R,5R,2'R,5'R)-5'-[(R)-1-(2,2,2-trifluoro-acetoxy)-undecyl]-octahydro-[2,2']bifuranyl-5-yl}-heptadec-14-ynyl ester

(+)-asimicin
102989-24-2

(+)-asimicin

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: Pd(PPh3)4; water / tetrahydrofuran / 2 h / 20 °C
2: AgNO3/SiO2 / hexane; CH2Cl2 / 2 h
3: KCN / methanol / 0.33 h
View Scheme
(4R,15R)-4,15-Bis-(2,2,2-trifluoro-acetoxy)-2-[(R)-2-(2,2,2-trifluoro-acetoxy)-prop-(Z)-ylidene]-15-{(2R,5R,2'R,5'R)-5'-[(R)-1-(2,2,2-trifluoro-acetoxy)-undecyl]-octahydro-[2,2']bifuranyl-5-yl}-pentadecanoic acid

(4R,15R)-4,15-Bis-(2,2,2-trifluoro-acetoxy)-2-[(R)-2-(2,2,2-trifluoro-acetoxy)-prop-(Z)-ylidene]-15-{(2R,5R,2'R,5'R)-5'-[(R)-1-(2,2,2-trifluoro-acetoxy)-undecyl]-octahydro-[2,2']bifuranyl-5-yl}-pentadecanoic acid

(+)-asimicin
102989-24-2

(+)-asimicin

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: AgNO3/SiO2 / hexane; CH2Cl2 / 2 h
2: KCN / methanol / 0.33 h
View Scheme
(2R,2'R,4R,4'R,5S,5'S)-4,4'-bis-(dimethylphenylsilanyl)-5-[(1R)-1-(tert-butyldimethylsilanyloxy)undecyl]-5'-[(1R,12R,16R)-1,12-bis-(tert-butyldimethylsilanyloxy)-16-(tert-butyldiphenylsilanyloxy)heptadec-14-yne]octahydro-2,2'-bifuran
863604-45-9

(2R,2'R,4R,4'R,5S,5'S)-4,4'-bis-(dimethylphenylsilanyl)-5-[(1R)-1-(tert-butyldimethylsilanyloxy)undecyl]-5'-[(1R,12R,16R)-1,12-bis-(tert-butyldimethylsilanyloxy)-16-(tert-butyldiphenylsilanyloxy)heptadec-14-yne]octahydro-2,2'-bifuran

(+)-asimicin
102989-24-2

(+)-asimicin

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1: TBAF / dimethylformamide; tetrahydrofuran / 6 h / 90 °C
2: 0.5 h / 20 °C
3: Pd(PPh3)4; water / tetrahydrofuran / 2 h / 20 °C
4: AgNO3/SiO2 / hexane; CH2Cl2 / 2 h
5: KCN / methanol / 0.33 h
View Scheme
(5S)-5-methyl-3-phenylsulfanyl-4,5-dihydrofuran-2(3H)-one
184435-75-4

(5S)-5-methyl-3-phenylsulfanyl-4,5-dihydrofuran-2(3H)-one

(+)-asimicin
102989-24-2

(+)-asimicin

Conditions
ConditionsYield
Multi-step reaction with 7 steps
1.1: i-Pr2NH; BuLi / tetrahydrofuran; hexane / 0.33 h / -78 °C
1.2: 54 percent / tetrahydrofuran; hexane; hexamethylphosphoric acid triamide / 19 h
2.1: m-CPBA / CH2Cl2 / 0.5 h / 0 °C
3.1: 0.191 g / toluene / 1 h / Heating
4.1: 89 percent / HF*pyridine / tetrahydrofuran / 25 h / 20 °C
5.1: 75 percent / Pd(PPh3)2Cl2; CuI; Et3N / 3.5 h / 20 °C
6.1: 73 percent / TsNHNH2; NaOAc / 1,2-dimethoxy-ethane; H2O / 4 h / Heating
7.1: 57 percent / aq. HCl / methanol; tetrahydrofuran / 15 h / 20 °C
View Scheme
(4R,5R)-8-Benzyloxy-4,5-bis-(tert-butyl-dimethyl-silanyloxy)-octanal
204572-66-7

(4R,5R)-8-Benzyloxy-4,5-bis-(tert-butyl-dimethyl-silanyloxy)-octanal

(+)-asimicin
102989-24-2

(+)-asimicin

Conditions
ConditionsYield
Multi-step reaction with 10 steps
1: 80 percent / InBr3 / ethyl acetate / -78 - 20 °C
2: 82 percent / pyridine
3: H2 / Pd/C
4: PCC
5: 74 percent / InBr3 / ethyl acetate / 18 h / 20 °C
6: 89 percent / pyridine / 21 h / 20 °C
7: 70 percent / TBAF / tetrahydrofuran / 18 h / 40 °C
8: 75 percent / Pd(PPh3)2Cl2; CuI; Et3N / 3.5 h / 20 °C
9: 73 percent / TsNHNH2; NaOAc / 1,2-dimethoxy-ethane; H2O / 4 h / Heating
10: 57 percent / aq. HCl / methanol; tetrahydrofuran / 15 h / 20 °C
View Scheme
Multi-step reaction with 10 steps
1: 80 percent / InBr3 / ethyl acetate / -78 - 20 °C
2: 82 percent / pyridine
3: H2 / Pd/C
4: PCC
5: 86 percent / InBr3 / ethyl acetate / -78 - 20 °C
6: 89 percent / pyridine / 21 h / 20 °C
7: 70 percent / TBAF / tetrahydrofuran / 18 h / 40 °C
8: 75 percent / Pd(PPh3)2Cl2; CuI; Et3N / 3.5 h / 20 °C
9: 73 percent / TsNHNH2; NaOAc / 1,2-dimethoxy-ethane; H2O / 4 h / Heating
10: 57 percent / aq. HCl / methanol; tetrahydrofuran / 15 h / 20 °C
View Scheme
Tributyl-((E)-(R)-1-methoxymethoxy-undec-2-enyl)-stannane

Tributyl-((E)-(R)-1-methoxymethoxy-undec-2-enyl)-stannane

(+)-asimicin
102989-24-2

(+)-asimicin

Conditions
ConditionsYield
Multi-step reaction with 10 steps
1: 80 percent / InBr3 / ethyl acetate / -78 - 20 °C
2: 82 percent / pyridine
3: H2 / Pd/C
4: PCC
5: 74 percent / InBr3 / ethyl acetate / 18 h / 20 °C
6: 89 percent / pyridine / 21 h / 20 °C
7: 70 percent / TBAF / tetrahydrofuran / 18 h / 40 °C
8: 75 percent / Pd(PPh3)2Cl2; CuI; Et3N / 3.5 h / 20 °C
9: 73 percent / TsNHNH2; NaOAc / 1,2-dimethoxy-ethane; H2O / 4 h / Heating
10: 57 percent / aq. HCl / methanol; tetrahydrofuran / 15 h / 20 °C
View Scheme
Multi-step reaction with 10 steps
1: 80 percent / InBr3 / ethyl acetate / -78 - 20 °C
2: 82 percent / pyridine
3: H2 / Pd/C
4: PCC
5: 86 percent / InBr3 / ethyl acetate / -78 - 20 °C
6: 89 percent / pyridine / 21 h / 20 °C
7: 70 percent / TBAF / tetrahydrofuran / 18 h / 40 °C
8: 75 percent / Pd(PPh3)2Cl2; CuI; Et3N / 3.5 h / 20 °C
9: 73 percent / TsNHNH2; NaOAc / 1,2-dimethoxy-ethane; H2O / 4 h / Heating
10: 57 percent / aq. HCl / methanol; tetrahydrofuran / 15 h / 20 °C
View Scheme
(E)-(4R,5R,8S,9R)-1-Benzyloxy-4,5-bis-(tert-butyl-dimethyl-silanyloxy)-9-methoxymethoxy-nonadec-10-en-8-ol
247200-04-0

(E)-(4R,5R,8S,9R)-1-Benzyloxy-4,5-bis-(tert-butyl-dimethyl-silanyloxy)-9-methoxymethoxy-nonadec-10-en-8-ol

(+)-asimicin
102989-24-2

(+)-asimicin

Conditions
ConditionsYield
Multi-step reaction with 9 steps
1: 82 percent / pyridine
2: H2 / Pd/C
3: PCC
4: 74 percent / InBr3 / ethyl acetate / 18 h / 20 °C
5: 89 percent / pyridine / 21 h / 20 °C
6: 70 percent / TBAF / tetrahydrofuran / 18 h / 40 °C
7: 75 percent / Pd(PPh3)2Cl2; CuI; Et3N / 3.5 h / 20 °C
8: 73 percent / TsNHNH2; NaOAc / 1,2-dimethoxy-ethane; H2O / 4 h / Heating
9: 57 percent / aq. HCl / methanol; tetrahydrofuran / 15 h / 20 °C
View Scheme
Multi-step reaction with 9 steps
1: 82 percent / pyridine
2: H2 / Pd/C
3: PCC
4: 86 percent / InBr3 / ethyl acetate / -78 - 20 °C
5: 89 percent / pyridine / 21 h / 20 °C
6: 70 percent / TBAF / tetrahydrofuran / 18 h / 40 °C
7: 75 percent / Pd(PPh3)2Cl2; CuI; Et3N / 3.5 h / 20 °C
8: 73 percent / TsNHNH2; NaOAc / 1,2-dimethoxy-ethane; H2O / 4 h / Heating
9: 57 percent / aq. HCl / methanol; tetrahydrofuran / 15 h / 20 °C
View Scheme
Toluene-4-sulfonic acid (1S,2R)-1-[(3R,4R)-3,4-bis-(tert-butyl-dimethyl-silanyloxy)-7-oxo-heptyl]-2-methoxymethoxy-dodecyl ester
247200-07-3

Toluene-4-sulfonic acid (1S,2R)-1-[(3R,4R)-3,4-bis-(tert-butyl-dimethyl-silanyloxy)-7-oxo-heptyl]-2-methoxymethoxy-dodecyl ester

(+)-asimicin
102989-24-2

(+)-asimicin

Conditions
ConditionsYield
Multi-step reaction with 6 steps
1: 74 percent / InBr3 / ethyl acetate / 18 h / 20 °C
2: 89 percent / pyridine / 21 h / 20 °C
3: 70 percent / TBAF / tetrahydrofuran / 18 h / 40 °C
4: 75 percent / Pd(PPh3)2Cl2; CuI; Et3N / 3.5 h / 20 °C
5: 73 percent / TsNHNH2; NaOAc / 1,2-dimethoxy-ethane; H2O / 4 h / Heating
6: 57 percent / aq. HCl / methanol; tetrahydrofuran / 15 h / 20 °C
View Scheme
Multi-step reaction with 6 steps
1: 86 percent / InBr3 / ethyl acetate / -78 - 20 °C
2: 89 percent / pyridine / 21 h / 20 °C
3: 70 percent / TBAF / tetrahydrofuran / 18 h / 40 °C
4: 75 percent / Pd(PPh3)2Cl2; CuI; Et3N / 3.5 h / 20 °C
5: 73 percent / TsNHNH2; NaOAc / 1,2-dimethoxy-ethane; H2O / 4 h / Heating
6: 57 percent / aq. HCl / methanol; tetrahydrofuran / 15 h / 20 °C
View Scheme
Toluene-4-sulfonic acid (1S,2R)-1-[(3R,4R)-3,4-bis-(tert-butyl-dimethyl-silanyloxy)-7-hydroxy-heptyl]-2-methoxymethoxy-dodecyl ester
247200-06-2

Toluene-4-sulfonic acid (1S,2R)-1-[(3R,4R)-3,4-bis-(tert-butyl-dimethyl-silanyloxy)-7-hydroxy-heptyl]-2-methoxymethoxy-dodecyl ester

(+)-asimicin
102989-24-2

(+)-asimicin

Conditions
ConditionsYield
Multi-step reaction with 7 steps
1: PCC
2: 74 percent / InBr3 / ethyl acetate / 18 h / 20 °C
3: 89 percent / pyridine / 21 h / 20 °C
4: 70 percent / TBAF / tetrahydrofuran / 18 h / 40 °C
5: 75 percent / Pd(PPh3)2Cl2; CuI; Et3N / 3.5 h / 20 °C
6: 73 percent / TsNHNH2; NaOAc / 1,2-dimethoxy-ethane; H2O / 4 h / Heating
7: 57 percent / aq. HCl / methanol; tetrahydrofuran / 15 h / 20 °C
View Scheme
Multi-step reaction with 7 steps
1: PCC
2: 86 percent / InBr3 / ethyl acetate / -78 - 20 °C
3: 89 percent / pyridine / 21 h / 20 °C
4: 70 percent / TBAF / tetrahydrofuran / 18 h / 40 °C
5: 75 percent / Pd(PPh3)2Cl2; CuI; Et3N / 3.5 h / 20 °C
6: 73 percent / TsNHNH2; NaOAc / 1,2-dimethoxy-ethane; H2O / 4 h / Heating
7: 57 percent / aq. HCl / methanol; tetrahydrofuran / 15 h / 20 °C
View Scheme
Toluene-4-sulfonic acid (E)-(1S,2R)-1-[(3R,4R)-7-benzyloxy-3,4-bis-(tert-butyl-dimethyl-silanyloxy)-heptyl]-2-methoxymethoxy-dodec-3-enyl ester
247200-05-1

Toluene-4-sulfonic acid (E)-(1S,2R)-1-[(3R,4R)-7-benzyloxy-3,4-bis-(tert-butyl-dimethyl-silanyloxy)-heptyl]-2-methoxymethoxy-dodec-3-enyl ester

(+)-asimicin
102989-24-2

(+)-asimicin

Conditions
ConditionsYield
Multi-step reaction with 8 steps
1: H2 / Pd/C
2: PCC
3: 74 percent / InBr3 / ethyl acetate / 18 h / 20 °C
4: 89 percent / pyridine / 21 h / 20 °C
5: 70 percent / TBAF / tetrahydrofuran / 18 h / 40 °C
6: 75 percent / Pd(PPh3)2Cl2; CuI; Et3N / 3.5 h / 20 °C
7: 73 percent / TsNHNH2; NaOAc / 1,2-dimethoxy-ethane; H2O / 4 h / Heating
8: 57 percent / aq. HCl / methanol; tetrahydrofuran / 15 h / 20 °C
View Scheme
Multi-step reaction with 8 steps
1: H2 / Pd/C
2: PCC
3: 86 percent / InBr3 / ethyl acetate / -78 - 20 °C
4: 89 percent / pyridine / 21 h / 20 °C
5: 70 percent / TBAF / tetrahydrofuran / 18 h / 40 °C
6: 75 percent / Pd(PPh3)2Cl2; CuI; Et3N / 3.5 h / 20 °C
7: 73 percent / TsNHNH2; NaOAc / 1,2-dimethoxy-ethane; H2O / 4 h / Heating
8: 57 percent / aq. HCl / methanol; tetrahydrofuran / 15 h / 20 °C
View Scheme
(E)-(2'R,5S)-3-(5'-iodo-2'-tert-butyldimethylsilyloxy)pent-4'-enyl-2,5-dihydro-5-methylfuran-2-one
313963-25-6

(E)-(2'R,5S)-3-(5'-iodo-2'-tert-butyldimethylsilyloxy)pent-4'-enyl-2,5-dihydro-5-methylfuran-2-one

(+)-asimicin
102989-24-2

(+)-asimicin

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: 89 percent / HF*pyridine / tetrahydrofuran / 25 h / 20 °C
2: 75 percent / Pd(PPh3)2Cl2; CuI; Et3N / 3.5 h / 20 °C
3: 73 percent / TsNHNH2; NaOAc / 1,2-dimethoxy-ethane; H2O / 4 h / Heating
4: 57 percent / aq. HCl / methanol; tetrahydrofuran / 15 h / 20 °C
View Scheme
(E,R)-5-iodo-4-pentene-1,2-diol
507480-50-4

(E,R)-5-iodo-4-pentene-1,2-diol

(+)-asimicin
102989-24-2

(+)-asimicin

Conditions
ConditionsYield
Multi-step reaction with 9 steps
1.1: 2,6-lutidine / CH2Cl2 / 0.5 h / -78 °C
2.1: 0.85 g / 2,6-lutidine / CH2Cl2 / 1.5 h / cooling
3.1: i-Pr2NH; BuLi / tetrahydrofuran; hexane / 0.33 h / -78 °C
3.2: 54 percent / tetrahydrofuran; hexane; hexamethylphosphoric acid triamide / 19 h
4.1: m-CPBA / CH2Cl2 / 0.5 h / 0 °C
5.1: 0.191 g / toluene / 1 h / Heating
6.1: 89 percent / HF*pyridine / tetrahydrofuran / 25 h / 20 °C
7.1: 75 percent / Pd(PPh3)2Cl2; CuI; Et3N / 3.5 h / 20 °C
8.1: 73 percent / TsNHNH2; NaOAc / 1,2-dimethoxy-ethane; H2O / 4 h / Heating
9.1: 57 percent / aq. HCl / methanol; tetrahydrofuran / 15 h / 20 °C
View Scheme
R-(+)-α-trifluoromethyl-α-methoxy-phenylacetic acid
20445-31-2

R-(+)-α-trifluoromethyl-α-methoxy-phenylacetic acid

(+)-asimicin
102989-24-2

(+)-asimicin

C67H87F9O13

C67H87F9O13

Conditions
ConditionsYield
With dmap; 1-hydroxybenzotriazol-hydrate; N,N-dimethyl-formamide; dicyclohexyl-carbodiimide In dichloromethane Ambient temperature;
(+)-asimicin
102989-24-2

(+)-asimicin

C67H87F9O13

C67H87F9O13

Conditions
ConditionsYield
With dmap; 1-hydroxybenzotriazol-hydrate; N,N-dimethyl-formamide; dicyclohexyl-carbodiimide In dichloromethane Ambient temperature;
(+)-asimicin
102989-24-2

(+)-asimicin

(S)-α-methoxynaphthalen-2-ylacetic acid
157134-51-5

(S)-α-methoxynaphthalen-2-ylacetic acid

C76H96O13

C76H96O13

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide In chloroform
(+)-asimicin
102989-24-2

(+)-asimicin

(R)-α-methoxynaphthalen-2-ylacetic acid
156942-67-5

(R)-α-methoxynaphthalen-2-ylacetic acid

C76H96O13

C76H96O13

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide In chloroform

102989-24-2Downstream Products

102989-24-2Relevant articles and documents

Convergent Total Synthesis of Asimicin via Decarbonylative Radical Dimerization

Kawamata, Takahiro,Yamaguchi, Akinori,Nagatomo, Masanori,Inoue, Masayuki

, p. 18907 - 18912 (2018)

Asimicin (1) exhibits potent antitumor activity and comprises a central C2-symmetric bis-tetrahydrofuran and two aliphatic side-chains, one of which terminates with (S)-methyl-2(5H)-furanone. This work reports a convergent total synthesis of 1 in 17 steps from d-gulose derivative 4. Decarbonylative radical-radial homo-coupling of α-alkoxyacyl telluride 12 a efficiently produced the C2-symmetric core 3-SS, which was transformed into 1 through stepwise attachment of the two side-chains and functional group manipulations.

Modular approach to Annonaceous acetogenins. Total synthesis of asimicin and bullatacin

Sinha, Subhash C.,Sinha-Bagchi, Anjana,Yazbak, Ahmad,Keinan, Ehud

, p. 9257 - 9260 (1995)

Starting with a variety of non-functionalized carbon skeletons and employing various combinations of five key transformations provides an easy access to most of the naturally occurring Annonaceous acetogenins. A particular emphasis is given to the dominant structural feature that appears in more than 40% of the known acetogenins. This is a linear, ten-carbon skeleton comprising two adjacent tetrahydrofurane rings flanked with two hydroxyl groups. Efficient, flexible syntheses of asimicin and bullatacin demonstrate this approach.

Alteration of the bis-tetrahydrofuran core stereochemistries in asimicin can affect the cytotoxicity

Sinha, Subhash C.,Chen, Zhiyong,Huang, Zheng-Zheng,Nakamaru-Ogiso, Eiko,Pietraszkiewicz, Halina,Edelstein, Matthew,Valeriote, Frederick

supporting information; experimental part, p. 7045 - 7048 (2009/11/30)

A systematic analysis using 10 synthetic asimicin stereoisomers revealed that the stereochemistry of the bis-tetrahydrofuran core, including the tetrahydrofuran rings and the adjacent hydroxy functions, had significant effect on its cytotoxicity. Our findings set to rest the highly controversial perception that the stereochemistry of the tetrahydrofuran core has little effect on the activity, which is not true for its cytotoxic effect, and also reinforces the previous conclusion that asimicin is a highly potent anticancer compound.

Total synthesis of asimicin via highly stereoselective [3 + 2] annulation reactions of substituted allylsilanes

Tinsley, Jennifer M.,Roush, William R.

, p. 10818 - 10819 (2007/10/03)

A highly stereoselective total synthesis of (+)-asimicin (1) is reported. The synthesis features two chelate-controlled [3 + 2] annulation reactions - one of which (e.g., 2 + 3) constitutes a key, convergent fragment assembly step - that establish all of the stereochemistry of the bis-tetrahydrofuran unit of the natural product. Copyright

A modular synthesis of annonaceous acetogenins

Marshall, James A.,Piettre, Arnaud,Paige, Mikell A.,Valeriote, Frederick

, p. 1771 - 1779 (2007/10/03)

A synthesis of four Annonaceous acetogenins, asiminocin, asimicin, asimin, and bullanin, by a modular approach from seven fundamental subunits, A-G, is described. The approach employs a central core aldehyde segment, C, to which are appended an aliphatic terminus, A or B, a spacer subunit, D or E, and a butenolide terminus, F or G. Coupling of the A, B, D, and E segments to the core aldehyde unit is effected by highly diastereoselective additions of enantiopure allylic indium or tin reagents. The butenolide termini are attached to the ACD, BCE, or BCD intermediates by means of a Sonogashira coupling. The design of the core, spacer, and termini subunits is such that any of the C30, C10, or C4 natural acetogenins or stereoisomers thereof could be prepared. IC50 values for the four aforementioned acetogenins against H-116 human colon cancer cells were found to be in the 10-3 to 10-4 μM range. The IC90 activities were ca. 10-3 μM for asimicin and asimin but only 0.1-1 μM for bullanin and asiminocin.

Total Synthesis of Asimicin and Bullatacin

Avedissian, Hovsep,Sinna, Santosh C.,Yazbak, Ahmad,Sinha, Anjana,Neogi, Partha,Sinha, Subhash C.,Keinan, Ehud

, p. 6035 - 6051 (2007/10/03)

The efficient total synthesis of asimicin, 1, and bullatacin, 2, has demonstrated the advantages of three different strategies for the synthesis of the tricyclic intermediates 6 and 7, which represent the key fragment of the bis-THF Annonaceous acetogenins. The naked carbon skeleton strategy is based on the production of all asymmetric centers by selective placement of the oxygen functions onto an unsaturated, nonfunctionalized carbon skeleton. Diversity in this approach arises from the relative timing of highly stereoselective reactions, such as the Sharpless asymmetric dihydroxylation (AD) reaction, the Kennedy oxidative cyclization (OC) with rhenium(VII) oxide, the Mitsunobu-type alcohol epimerization reaction, and the Williamson etherification reaction. The convergent strategy, which is based on the combinatorial coupling of two series of diastereomeric fragments, to produce intermediates such as 11 and 12, enjoys the advantages of both efficiency and versatility. The third approach, which is based on partially functionalized intermediates, such as 13, combines the advantages of both the linear and the convergent strategies-synthetic efficiency and diversity.

Total synthesis of the Annonaceous acetogenin (+)-asimicin. Development of a new bidirectional strategy

Marshall, James A.,Hinkle, Kevin W.

, p. 5989 - 5995 (2007/10/03)

The total synthesis of the Annonaceous acetogenin (+)-asimicin is described. The approach employs the (R)-α-OSEM allylic stannane 7 of >95% ee and the dialdehyde 8 obtained from (S,S)-diethyl tartrate. Addition of 7 to 8 in the presence of InCl3 afforded the bis-adduct 9 in 71% yield. Tosylation and treatment with TBAF led to the core bis-tetrahydrofuran intermediate, diol 11, in 78% yield. Mono tosylation (n-BuLi, TsCl, THF-DMSO) and subsequent hydrogenolysis with LiBEt3H gave alcohol 14. The iodide 15 was coupled with the higher-order vinylcyanocuprate to afford olefin 30. This was converted to diol 31 of high ee by the Sharpless protocol. This diol yielded the epoxide 33 via the mono-trisylate 32. Addition of (R)-lithio-2-(OTBS)-3- butyne in the presence of BF3·OEt2 afforded the alcohol 34. The SEM derivative 35 was treated with TBAF, and the resulting alcohol was converted to the butenolide 38 by a sequence involving treatment with (CF3CO)2O, then Pd(PPh3)4, CO, THF-H2O, and finally AgNO3/silica gel. Cleavage of the SEM protecting group with PPTS in ethanol afforded (+)-asimicin (39).

Total synthesis of the potent antitumor, bis-tetrahydrofuranyl annonaceous acetogenins (+)-asimicin and (+)-bullatacin

Hoye, Thomas R.,Tan, Lushi

, p. 1981 - 1984 (2007/10/02)

Convergent syntheses of the title compounds involve: a bis-THF-subunit preparation via Sharpless' double asymmetric dihydroxylation and subsequent asymmetric epoxidation; preparation of the C(4)-hydroxybutenolide-containing subunit using a Stille butenolide synthesis: Pd°-mediated coupling of these vinyl iodide and alkyne subunits; and selective Wilkinson reduction of the resulting enyne.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 102989-24-2